Recombinant Varicella Zoster Virus Glycoprotein E Vaccine
Yes
Yes
Subsidised Vaccine List
Active ingredients: Vaccine Zoster | Zoster Vaccine | Recombinant Varicella Zoster Virus Glycoprotein E Vaccine Synonyms: Herpes Zoster Vaccine | Shingles Vaccine
General information
Subsidy Information and Financing Scheme
[SVL] Recombinant Varicella Zoster Virus Glycoprotein E Vaccine (Shingrix) Injection 50 mcg/0.5 mL
National Adult Immunisation Schedule (NAIS)
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in:
adults 60 years of age or older; and
adults 18 years of age or older at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.
Funding status
[R] Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection is recommended for inclusion on the MOH Subsidised Vaccine List (SVL) for the abovementioned indication from September 2025.
[R] The recombinant varicella zoster virus glycoprotein E injection should be used in line with the additional clinical criteria listed in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Shingrix Injection 50 mcg/0.5 mL |
|
List of monographs containing this active ingredient
Recombinant Varicella Zoster Virus Glycoprotein E Vaccine [Shingrix]
